SYNBV invest up to $2m in East to West subsidiary
Filed with ASX · · 5 pages · English
Summary by 6ix AI
This investment will support planning and preparation for clinical development of three cellular immunotherapy assets being considered for licensing by AdCella. Completion of the transaction is expected before mid-April and is subject to final agreements and regulatory compliance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- R&D Tax Incentive advance received
- Investor Presentation
- East to West cell therapy strategy update
- AD-214 clinical advisory board
- FY24 RDTI Refund Received $1.77m
Later from AdAlta
- Trading Halt
- Renounceable Rights Issue to Raise up to $1.3 million
- Prospectus
- Notice of change of exercise price of options
- Rights Issue raises $1.1million
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta